Soraya Bekkali
SVP, EUCAN and International Business
About Delphine
Delphine brings extensive expertise in corporate affairs, policy engagement, patient advocacy, access strategy, strategic planning, and building high-performing teams. She joins from MSD, where she served as Associate Vice President, Sustainable Access Solutions within the Global Market Access organization.
Prior to MSD, Delphine held several senior leadership positions at Biogen and earlier in her career, she led European affairs and patient advocacy initiatives at LEEM, the French pharmaceutical industry association.
Throughout her career, Delphine has been driven by a commitment to improving outcomes for patients and helping healthcare systems sustainably adopt innovation. She has worked closely with patient communities across multiple therapeutic areas, including rare diseases, and understands the critical role that advocacy, policy and stakeholder partnerships play in accelerating diagnosis, access and support for patients and their families.
Related Content
Patient Support • June 25, 2024
Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice
Artificial Intelligence (AI) is rapidly advancing and has the potential to have a transformative impact on clinical research and development (R&D).
Research and Development • June 08, 2024
Getting to know Seng Cheng, an Alexion R&D Leading Voice
There is a sense of urgency that underlies research in rare diseases, because these diseases are often rapidly progressive.
Patient Support • April 18, 2024
Getting to know Sophia Zilber, Associate Director, Statistical Programming
The voices and perspectives of patients play an essential role in rare disease research and development (R&D).
Patient Support • April 16, 2024
Getting to know Banu Sankaran, an Alexion R&D Leading Voice
Diagnostics and artificial intelligence (AI) systems are transforming research and development (R&D) in the healthcare industry.
Health Equity • February 06, 2024
Driving health equity for the rare disease community
Collectively, more than 400 million people around the world are living with a rare disease, defined as conditions that affect a small number of people compared to the general population.
Patient Support • November 08, 2023
Getting to Know Mary Kunjappu, an Alexion R&D Leading Voice
Science is hard, but rare disease research and development (R&D) stands apart. Because individual patient populations are small and many rare diseases are not well understood, research in this space can often bring added complexity.
Clinical Trials • November 07, 2023
Understanding & Overcoming the Challenges in Rare Disease Clinical Trials
Why is conducting clinical trials for rare diseases difficult? Because studying a rare disease poses unique challenges and requires thinking differently.
Clinical Trials • November 01, 2023
Getting to know Adrian Kielhorn, an Alexion R&D Leading Voice
Alexion’s leadership in rare disease is driven by the many individuals whose expertise, creativity and tenacity fuel our commitment to advancing innovative science.
Patient Support • June 30, 2023
Children’s Book Series is Inspired By Patients Living with Rare Diseases
At Alexion, our mission is to transform the lives of people affected by rare diseases and one of the tangible ways we raise awareness is by developing tools and resources to educate about the impact of rare diseases on patients, caregivers, and families.
Veeva ID: GL/ALL/0121